Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

MEI Gets Another Chance At PI3K Inhibitor With Infinity Merger

Feb 23 2023

• By Joseph Haas

M&A — MEI and Infinity announce the latest merger of smaller, clinical-stage biotechs • Source: Shutterstock

Related Content

Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives

Feb 21 2023

Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse

Mar 25 2022

MEI/Kyowa Kirin Show More Data Supporting Zandelisib’s Safety Profile

Jun 10 2022

Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

Mar 11 2019

Financing Available For Some, But Not All Biopharma Companies In 2023

Jan 18 2023

Related Companies

Lite Strategy, Inc.

Infinity Pharmaceuticals, Inc.

Kyowa Kirin Co., Ltd.

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

M & A Business Strategies Deals Commercial Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window